|
1
|
Van Cutsem E, Twelves C, Cassidy J, et al:
Oral capecitabine compared with intravenous fluorouracil plus
leucovorin in patients with metastatic colorectal cancer: results
of a large phase III study. J Clin Oncol. 19:4097–4106. 2001.
|
|
2
|
Blum JL, Dieras V, Lo Russo PM, et al:
Multicenter, phase II study of capecitabine in taxane-pretreated
metastatic breast carcinoma patients. Cancer. 92:1759–1768. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Twelves C, Wong A, Nowacki MP, et al:
Capecitabine as adjuvant treatment for stage III colon cancer. N
Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bang YJ: Capecitabine in gastric cancer.
Expert Rev Anticancer Ther. 11:1791–1806. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scheithauer W and Blum J: Coming to grips
with hand-foot syndrome. Insights from clinical trials evaluating
capecitabine. Oncology (Williston Park). 18:1161–1168; discussion
1173–1176. 1181–1184. 2004.PubMed/NCBI
|
|
6
|
Nagore E, Insa A and Sanmartin O:
Antineoplastic therapy-induced palmar plantar erythrodysesthesia
(‘hand-foot’) syndrome. Incidence, recognition and management. Am J
Clin Dermatol. 1:225–234. 2000.
|
|
7
|
Gressett SM, Stanford BL and Hardwicke F:
Management of hand-foot syndrome induced by capecitabine. J Oncol
Pharm Pract. 12:131–141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chiara S, Nobile MT, Barzacchi C, et al:
Hand-foot syndrome induced by high-dose, short-term, continuous
5-fluorouracil infusion. Eur J Cancer. 33:967–969. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vukelja SJ, Lombardo FA, James WD and
Weiss RB: Pyridoxine for the palmar-plantar erythrodysesthesia
syndrome. Ann Intern Med. 111:688–689. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fabian CJ, Molina R, Slavik M, Dahlberg S,
Giri S and Stephens R: Pyridoxine therapy for palmar-plantar
erythrodysesthesia associated with continuous 5-fluorouracil
infusion. Invest New Drugs. 8:57–63. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yusuf S, Peto R, Lewis J, Collins R and
Sleight P: Beta blockade during and after myocardial infarction: an
overview of the randomized trials. Prog Cardiovasc Dis. 27:335–371.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Macaskill P, Walter SD and Irwig L: A
comparison of methods to detect publication bias in meta-analysis.
Stat Med. 20:641–654. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mortimer JE, Lauman MK, Tan B, Dempsey CL,
Shillington AC and Hutchins KS: Pyridoxine treatment and prevention
of hand-and-foot syndrome in patients receiving capecitabine. J
Oncol Pharm Pract. 9:161–166. 2003. View Article : Google Scholar
|
|
16
|
Corrie PG, Bulusu R, Wilson CB, et al: A
randomised study evaluating the use of pyridoxine to avoid
capecitabine dose modifications. Br J Cancer. 107:585–587. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
18
|
Lokich JJ and Moore C:
Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.
Ann Intern Med. 101:798–799. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Banfield GK, Crate ID and Griffiths CL:
Long-term sequelae of palmar-plantar erythrodysaesthesia syndrome
secondary to 5-fluorouracil therapy. J R Soc Med. 88:356P–357P.
1995.PubMed/NCBI
|
|
20
|
Zimmerman GC, Keeling JH, Burris HA, et
al: Acute cutaneous reactions to docetaxel, a new chemotherapeutic
agent. Arch Dermatol. 131:202–206. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gordon KB, Tajuddin A, Guitart J, Kuzel
TM, Eramo LR and VonRoenn J: Hand-foot syndrome associated with
liposome-encapsulated doxorubicin therapy. Cancer. 75:2169–2173.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abushullaih S, Saad ED, Munsell M and Hoff
PM: Incidence and severity of hand-foot syndrome in colorectal
cancer patients treated with capecitabine: a single-institution
experience. Cancer Invest. 20:3–10. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin E, Morris JS and Ayers GD: Effect of
celecoxib on capecitabine-induced hand-foot syndrome and antitumor
activity. Oncology (Williston Park). 16:31–37. 2002.PubMed/NCBI
|
|
24
|
Lopez AM, Wallace L, Dorr RT, Koff M,
Hersh EM and Alberts DS: Topical DMSO treatment for pegylated
liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
Cancer Chemother Pharmacol. 44:303–306. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Andres R, Mayordomo JI, Lara R, et al:
Gemcitabine/capecitabine in patients with metastatic breast cancer
pretreated with anthracyclines and taxanes. Clin Breast Cancer.
6:158–162. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chalermchai T, Tantiphlachiva K,
Suwanrusme H, Voravud N and Sriuranpong V: Randomized trial of two
different doses of pyridoxine in the prevention of
capecitabine-associated palmar-plantar erythrodysesthesia. Asia Pac
J Clin Oncol. 6:155–160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rossi D and Catalano G: Pyridoxine as
prophylactic therapy for palmar-plantar erythrodysesthesia
associated with administration of pegylated liposomal doxorubicin
(caelyx): a single-center experience. Oncology. 73:277–278. 2007.
View Article : Google Scholar
|
|
28
|
Stewart LA and Parmar MK: Meta-analysis of
the literature or of individual patient data: is there a
difference? Lancet. 341:418–422. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Begg CB and Mazumdar M: Operating
characteristics of a rank correlation test for publication bias.
Biometrics. 50:1088–1101. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoshimoto N, Yamashita T, Fujita T, et al:
Impact of prophylactic pyridoxine on occurrence of hand-foot
syndrome in patients receiving capecitabine for advanced or
metastatic breast cancer. Breast Cancer. 17:298–302. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kang YK, Lee SS, Yoon DH, et al:
Pyridoxine is not effective to prevent hand-foot syndrome
associated with capecitabine therapy: results of a randomized,
double-blind, placebo-controlled study. J Clin Oncol. 28:3824–3829.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Braik T, Yim B, Evans AT, et al: A
randomized trial to determine if vitamin B6 can prevent hand and
foot syndrome in cancer patients treated with capecitabine
chemotherapy. J Clin Oncol. 30(Suppl): abstr 9085. 2012.
|
